Wellspring Biosciences LLC

11 patents currently held · Updated Nov 15, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Sep 2035

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Dec 13, 2026
The maintenance fee for Substituted Inhibitors of Menin-Mll and Methods of Use (US 11,673,898) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
1 fee due Sep 17, 2027
The maintenance fee for Methods and Compositions for Inhibiting the Interaction of Menin with MLL Proteins (US 10,588,907) comes due Sep 17, 2027. Unpaid by Mar 17, 2028, it lapses early.
1 fee due Oct 2, 2027
The maintenance fee for Methods for Treating Hematological Malignancies and Ewing's Sarcoma (US 11,944,627) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Patent	Title	Status	Expires	Confidence
US RE49,687	Thienopyrimidine and Thienopyridine Compounds and Methods of Use Thereof In force Term ends Sep 8, 2035 · Low confidence	In force	Term ends Sep 8, 2035	Low confidence
US 10,077,271	Methods and Compositions for Inhibiting the Interaction of Menin with MLL Proteins In force Term ends Mar 16, 2036 · High confidence	In force	Term ends Mar 16, 2036	High confidence
US 10,174,041	Methods and Compositions for Inhibiting the Interaction of Menin with MLL Proteins In force Term ends Mar 16, 2036 · High confidence	In force	Term ends Mar 16, 2036	High confidence
US 10,588,907	Methods and Compositions for Inhibiting the Interaction of Menin with MLL Proteins In force Term ends Jun 3, 2036 · High confidence	In force	Term ends Jun 3, 2036	High confidence
US 10,752,639	Bridged Bicyclic Inhibitors of Menin-Mll and Methods of Use In force Term ends Mar 15, 2037 · High confidence	In force	Term ends Mar 15, 2037	High confidence
US 10,781,218	Substituted Inhibitors of Menin-Mll and Methods of Use In force Term ends Mar 15, 2037 · High confidence	In force	Term ends Mar 15, 2037	High confidence
US 11,555,041	Bridged Bicyclic Inhibitors of Menin-Mll and Methods of Use In force Term ends Mar 15, 2037 · High confidence	In force	Term ends Mar 15, 2037	High confidence
US 11,673,898	Substituted Inhibitors of Menin-Mll and Methods of Use In force Term ends Mar 15, 2037 · High confidence	In force	Term ends Mar 15, 2037	High confidence
US 11,944,627	Methods for Treating Hematological Malignancies and Ewing's Sarcoma In force Term ends Sep 6, 2038 · High confidence	In force	Term ends Sep 6, 2038	High confidence
US 11,649,251	Substituted Inhibitors of Menin-Mll and Methods of Use In force Term ends Sep 19, 2038 · High confidence	In force	Term ends Sep 19, 2038	High confidence

10 of 11 patents shown.

Pro members see all 11.

Pro members: see all 11 patents

Also on record, not counted in the 11: 1 surrendered on reissue. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro